Understand the source comparison
Anti-Aging & Longevity Peptides Compared: Mechanism Comparison
The table below compares four major anti-aging peptide categories by primary mechanism, target pathway, typical research dose, and experimental model compatibility. Use this to match peptide selection to your study's biological question. Epithalon Telomerase a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares four major anti-aging peptide categories by primary mechanism, target pathway, typical research dose, and experimental model compatibility. Use this to match peptide selection to your study's biological question.
- Epithalon
- Telomerase activation
- Telomere maintenance, TERT upregulation
- 5–10mg/day subcutaneous, 10–20 day cycle
- Cellular senescence models, replicative aging studies, chromosome stability assays
- Best for chromosomal aging endpoints; ineffective in acute mitochondrial dysfunction models
- SS-31 (Elamipretide)
- Cardiolipin stabilization
- Mitochondrial cristae preservation, ETC supercomplex integrity
- 0.25–4mg/kg daily subcutaneous or IV
- Cardiac aging, skeletal muscle mitochondrial studies, ischemia-reperfusion injury
- Gold standard for mitochondrial function; no effect on telomere length or immune markers
- Thymalin
- Thymic epithelial cell activation
- T-cell maturation, CD4+ restoration, adaptive immunity
- 5–10mg IM every other day, 10 injection series
- Immunosenescence studies, vaccine response models, infection susceptibility assays
- Effective for immune aging only; irrelevant to cellular senescence or mitochondrial pathways
- FOXO4-DRI
- p53-FOXO4 disruption
- Senescent cell apoptosis, SASP reduction
- 5–25mg every 3–4 days subcutaneous
- Senescent cell clearance models, age-related inflammation, tissue regeneration studies
- Highly selective senolytic; requires acidic reconstitution to prevent aggregation
- Notice the 'Best Experimental Model' column. This is where most protocol design errors occur. A researcher studying cardiac aging in a mitochondrial disease model who selects Epithalon instead of SS-31 won't generate data addressing the research question. Telomerase activation doesn't restore ATP synthesis in dysfunctional mitochondria.